{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T07:43:48Z","timestamp":1794296628004,"version":"4.9.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Prostate-specific membrane antigen (PSMA)\u2013targeting PET radiotracers reveal physiologic uptake in the urinary system, potentially misrepresenting activity in the prostatic urethra as an intraprostatic lesion. This study examined the correlation between midline <jats:sup>18<\/jats:sup>F-DCFPyL activity in the prostate and hyperintensity on T2-weighted (T2W) MRI as an indication of retained urine in the prostatic urethra.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods<\/jats:title>\n            <jats:p>Eighty-five patients who underwent both <jats:sup>18<\/jats:sup>F-DCFPyL PSMA PET\/CT and prostate MRI between July 2017 and September 2023 were retrospectively analyzed for midline radiotracer activity and retained urine on postvoid T2W MRIs. Fisher's exact tests and unpaired <jats:italic toggle=\"yes\">t<\/jats:italic> tests were used to compare residual urine presence and prostatic urethra measurements between patients with and without midline radiotracer activity. The influence of anatomical factors including prostate volume and urethral curvature on urinary stagnation was also explored.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Midline activity on PSMA PET imaging was seen in 14 patients included in the case group, whereas the remaining 71 with no midline activity constituted the control group. A total of 71.4% (10\/14) and 29.6% (21\/71) of patients in the case and control groups had urethral hyperintensity on T2W MRI, respectively (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.01). Patients in the case group had significantly larger mean urethral dimensions, larger prostate volumes, and higher incidence of severe urethral curvature compared with the controls.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Stagnated urine within the prostatic urethra is a potential confounding factor on PSMA PET scans. Integrating PET imaging with T2W MRI can mitigate false-positive calls, especially as PSMA PET\/CT continues to gain traction in diagnosing localized prostate cancer.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000005220","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T13:00:19Z","timestamp":1713877219000},"page":"630-636","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Reducing False-Positives Due to Urinary Stagnation in the Prostatic Urethra on 18F-DCFPyL PSMA PET\/CT With MRI"],"prefix":"10.1097","volume":"49","author":[{"given":"David G.","family":"Gelikman","sequence":"first","affiliation":[{"name":"Molecular Imaging Branch"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Mena","sequence":"additional","affiliation":[{"name":"Molecular Imaging Branch"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza","family":"Lindenberg","sequence":"additional","affiliation":[{"name":"Molecular Imaging Branch"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S.","family":"Azar","sequence":"additional","affiliation":[{"name":"Urologic Oncology Branch"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nityam","family":"Rathi","sequence":"additional","affiliation":[{"name":"Urologic Oncology Branch"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enis C.","family":"Yilmaz","sequence":"additional","affiliation":[{"name":"Molecular Imaging Branch"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie A.","family":"Harmon","sequence":"additional","affiliation":[{"name":"Molecular Imaging Branch"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle C.","family":"Schuppe","sequence":"additional","affiliation":[{"name":"Urologic Oncology Branch"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica Y.","family":"Hsueh","sequence":"additional","affiliation":[{"name":"Urologic Oncology Branch"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Huth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradford J.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Gurram","sequence":"additional","affiliation":[{"name":"Urologic Oncology Branch"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"Choyke","sequence":"additional","affiliation":[{"name":"Molecular Imaging Branch"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Pinto","sequence":"additional","affiliation":[{"name":"Urologic Oncology Branch"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baris","family":"Turkbey","sequence":"additional","affiliation":[{"name":"Molecular Imaging Branch"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,4,19]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/1078-1439(95)00002-Y","article-title":"Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues","volume":"1","year":"1995","journal-title":"Urol Oncol"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41585-022-00618-w","article-title":"The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer","volume":"19","year":"2022","journal-title":"Nat Rev Urol"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","year":"2020","journal-title":"Lancet"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial","volume":"5","year":"2019","journal-title":"JAMA Oncol"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","article-title":"The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study","volume":"80","year":"2021","journal-title":"Eur Urol"},{"key":"bib7-20250621","first-page":"1644","article-title":"The PRIMARY score: using Intraprostatic (68)Ga-PSMA PET\/CT patterns to optimize prostate cancer diagnosis","volume":"63","year":"2022","journal-title":"J Nucl Med"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1007\/s00261-020-02427-4","article-title":"Positron emission tomography (PET) radiotracers for prostate cancer imaging","volume":"45","year":"2020","journal-title":"Abdom Radiol (NY)"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40644-017-0133-5","article-title":"(68)Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer","volume":"17","year":"2017","journal-title":"Cancer Imaging"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1007\/s00259-017-3725-1","article-title":"Development of standardized image interpretation for 68Ga-PSMA PET\/CT to detect prostate cancer recurrent lesions","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00259-021-05520-y","article-title":"Prospective intra-individual blinded comparison of [(18)F]PSMA-1007 and [(68) Ga]Ga-PSMA-11 PET\/CT imaging in patients with confirmed prostate cancer","volume":"49","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00259-016-3578-z","article-title":"Early dynamic imaging in (68)Ga-PSMA-11 PET\/CT allows discrimination of urinary bladder activity and prostate cancer lesions","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41391-020-00292-2","article-title":"Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology","volume":"24","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1148\/rg.254045155","article-title":"Imaging of pelvic malignancies with in-line FDG PET-CT: case examples and common pitfalls of FDG PET","volume":"25","year":"2005","journal-title":"Radiographics"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev-med-063014-123902","article-title":"Management of benign prostatic hyperplasia","volume":"67","year":"2016","journal-title":"Annu Rev Med"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/CCO.0000000000000515","article-title":"Contemporary treatments in prostate cancer focal therapy","volume":"31","year":"2019","journal-title":"Curr Opin Oncol"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.acra.2020.03.017","article-title":"Quantitative characterization of the prostatic urethra using MRI: implications for lower urinary tract symptoms in patients with benign prostatic hyperplasia","volume":"28","year":"2021","journal-title":"Acad Radiol"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrurol.2016.26","article-title":"Current use of PSMA-PET in prostate cancer management","volume":"13","year":"2016","journal-title":"Nat Rev Urol"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.eururo.2018.03.030","article-title":"Impact of (68)Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis","volume":"74","year":"2018","journal-title":"Eur Urol"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.euo.2020.11.002","article-title":"The role of magnetic resonance imaging and positron emission tomography\/computed tomography in the primary staging of newly diagnosed prostate cancer: a systematic review of the literature","volume":"4","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"bib21-20250621","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/JU.0000000000000198","article-title":"Imaging of prostate specific membrane antigen targeted radiotracers for the detection of prostate cancer biochemical recurrence after definitive therapy: a systematic review and meta-analysis","volume":"202","year":"2019","journal-title":"J Urol"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/bju.14944","article-title":"Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature","volume":"125","year":"2020","journal-title":"BJU Int"},{"key":"bib23-20250621","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41391-019-0156-z","article-title":"Performance of [(68)Ga] Ga-PSMA 11 PET for detecting prostate cancer in the lymph nodes before salvage lymph node dissection: a systematic review and meta-analysis","volume":"23","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"bib24-20250621","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41585-022-00670-6","article-title":"Using PSMA imaging for prognostication in localized and advanced prostate cancer","volume":"20","year":"2023","journal-title":"Nat Rev Urol"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40644-019-0211-y","article-title":"Intra-individual comparison of (68)Ga-PSMA-11 and (18)F-DCFPyL normal-organ biodistribution","volume":"19","year":"2019","journal-title":"Cancer Imaging"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s11307-015-0850-8","article-title":"Initial evaluation of [(18)F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer","volume":"17","year":"2015","journal-title":"Mol Imaging Biol"},{"key":"bib27-20250621","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1007\/s00259-019-04620-0","article-title":"(68)Ga-PSMA PET\/CT better characterises localised prostate cancer after MRI and transperineal prostate biopsy: is (68)Ga-PSMA PET\/CT guided biopsy the future?","volume":"47","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib28-20250621","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.euf.2021.01.016","article-title":"The role of PSMA PET\/CT and PET\/MRI in the initial staging of prostate cancer","volume":"7","year":"2021","journal-title":"Eur Urol Focus"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005220","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:01:38Z","timestamp":1750532498000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,19]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005220","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,19]]}}}